Evidence map›Paper›PMID 25355836›Full record

ArticleNeurology2014

Mutations in Twinkle primase-helicase cause Perrault syndrome with neurologic features.

Hiroyuki Morino, Sarah B Pierce, Yukiko Matsuda, Tom Walsh, Ryosuke Ohsawa, Marta Newby, Keiko Hiraki-Kamon, Masahito Kuramochi, Ming K Lee, Rachel E Klevit and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 107 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The First HeterozygousBiomolecules · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Genetic insights into the complexity of premature ovarian insufficiency.Reproductive biology and endocrinology : RB&E · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Hiroyuki MorinoFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Sarah B PierceFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas. hkawakam@hiroshima-u.ac.jp sbpierce@uw.edu.
Yukiko MatsudaFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Tom WalshFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Ryosuke OhsawaFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Marta NewbyFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Keiko Hiraki-KamonFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Masahito KuramochiFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Ming K LeeFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Rachel E KlevitFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Alan MartinFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Hirofumi MaruyamaFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Mary-Claire KingFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas.
Hideshi KawakamiFrom the Department of Epidemiology, Research Institute for Radiation Biology and Medicine (H. Morino, Y.M., R.O., K.H.-K., M.K., H.K.), and Department of Clinical Neuroscience & Therapeutics (H. Maruyama), Hiroshima University, Japan; Departments of Medicine (Medical Genetics) and Genome Sciences (S.B.P., T.W., M.K.L., M.-C.K.) and Biochemistry (R.E.K.), University of Washington, Seattle; and Neuromuscular Center (M.N., A.M.), Texas Health Presbyterian Hospital, Dallas. hkawakam@hiroshima-u.ac.jp sbpierce@uw.edu.
University of Washington · US

Funding

Discovery of New Genes for Inherited Predisposition to Breast Cancer by Exome SeqR01CA157744 · NCI · UNIVERSITY OF WASHINGTON · PI KING, MARY-CLAIRE, WALSH, TOMAS D · 2011 to 2015
$2.7M
NCI NIH HHS R01 CA157744
6 · The paper itself

Abstract

objectiveTo identify the genetic cause in 2 families of progressive ataxia, axonal neuropathy, hyporeflexia, and abnormal eye movements, accompanied by progressive hearing loss and ovarian dysgenesis, with a clinical diagnosis of Perrault syndrome.

methodsWhole-exome sequencing was performed to identify causative mutations in the 2 affected sisters in each family. Family 1 is of Japanese ancestry, and family 2 is of European ancestry.

resultsIn family 1, affected individuals were compound heterozygous for chromosome 10 open reading frame 2 (C10orf2) p.Arg391His and p.Asn585Ser. In family 2, affected individuals were compound heterozygous for C10orf2 p.Trp441Gly and p.Val507Ile. C10orf2 encodes Twinkle, a primase-helicase essential for replication of mitochondrial DNA. Conservation and structural modeling support the causality of the mutations. Twinkle is known also to harbor multiple mutations, nearly all missenses, leading to dominant progressive external ophthalmoplegia type 3 and to recessive mitochondrial DNA depletion syndrome 7, also known as infantile-onset spinocerebellar ataxia.

conclusionsOur study identifies Twinkle mutations as a cause of Perrault syndrome accompanied by neurologic features and expands the phenotypic spectrum of recessive disease caused by mutations in Twinkle. The phenotypic heterogeneity of conditions caused by Twinkle mutations and the genetic heterogeneity of Perrault syndrome call for genomic definition of these disorders.

Indexed as

AdultAmino Acid SequenceDNA HelicasesFemaleGonadal Dysgenesis, 46,XXHearing Loss, SensorineuralHumansMitochondrial ProteinsMolecular Sequence DataMutationNervous System DiseasesPedigreeProtein Structure, SecondaryProtein Structure, TertiaryDNA HelicasesMitochondrial ProteinsTWNK protein, human

Identifiers

PMID25355836
PMCPMC4248451
OpenAlexW2063465467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.